Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order, and online pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.
Frequently asked questions
What sector does Medicure Inc (MPH) operate in?
Medicure Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Medicure Inc (MPH) current stock price?
As of the latest data, Medicure Inc stock price is CA$1.36, with a previous close of CA$1.28. Medicure Inc gained CA$0.08 in the last trading session, representing a 6.25% increase.
What is Medicure Inc (MPH) current market capitalization?
Medicure Inc market cap is approximately 14.19 million.
What is Medicure Inc (MPH) Earnings Per Share (EPS)?
The trailing EPS is -CA$0.65.
Does Medicure Inc (MPH) pay dividends?
No. Medicure Inc does not pay a dividend.
When is Medicure Inc (MPH) next earnings report?
Medicure Inc is expected to release its next earnings report on June 30, 2026.
What is Medicure Inc (MPH) beta (volatility) score?
Medicure Inc has a beta of 1.038, meaning its volatility is roughly in line with the market.
